Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.

The Journal of urology - 1 Aug 2001

Kielb S J, Shah N L, Rubin M A, Sanda M G

Abstract excerpt

PURPOSE: Paclitaxel and gemcitabine are promising new agents for treatment of human bladder cancer. We determine how the presence or absence of p53 function impacts the cytotoxic effects of these chemotherapeutic agents in human bladder cancer. MATERIALS AND METHODS: The J82 human bladder cancer (TCC) cell line was transfected with a temperature sensitive p53 (tsp53) mutant that functions as mutated p53 at 37C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Death

Share to Deoxycytidine

Share to Drug Screening Assays, Antitumor

Share to Gemcitabine

Share to Paclitaxel

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 11458051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.PMID 11458051Read ↗

Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.Semantic proximity Read ↗

Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.Semantic proximity Read ↗

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.Semantic proximity Read ↗

Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.Semantic proximity Read ↗

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.Semantic proximity Read ↗

The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.Semantic proximity Read ↗

P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.Semantic proximity Read ↗

Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.Semantic proximity Read ↗

Human urinary bladder epithelial cells lacking wild-type p53 function are deficient in the repair of 4-aminobiphenyl-DNA adducts in genomic DNA.Semantic proximity Read ↗

Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cellsSemantic proximity Read ↗

Mutations of TP53 do not correlate with the sensitivity to paclitaxel--a study using 27 gynaecological cancer cell lines.Semantic proximity Read ↗

Relationship between radiation response and p53 status in human bladder cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.